Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1812329 | 1.00 | TP53 (0.41) | TP53TSHRSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL2686070 | 1.00 | TP53 (0.41) | TP53TSHRSMN1; SMN2ALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL384129 | 0.98 | TP53 (0.40) | TP53TSHRSMN1; SMN2ALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL28583358 | 0.98 | TP53 (0.40) | TP53TSHRSMN1; SMN2ALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL928017 | 0.98 | TP53 (0.40) | TP53TSHRSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL14136794 | 0.87 | TSHR (0.47) | TSHRSMN1; SMN2ALDH1A1MAPK1CYP2C19 | |
| SCHEMBL8216463 | 0.87 | TSHR (0.47) | TSHRSMN1; SMN2ALDH1A1MAPK1CYP2C19 | |
| SCHEMBL969793 | 0.87 | TSHR (0.47) | TSHRSMN1; SMN2ALDH1A1MAPK1CYP2C19 | |
| SCHEMBL363726 | 0.86 | TP53 (0.48) | TP53TSHRSMN1; SMN2ALDH1A1CYP2C19 | |
| Hydrochloric Acid SCHEMBL928631 | 0.85 | TSHR (0.46) | TSHRSMN1; SMN2ALDH1A1MAPK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571881-A1 | PYRROLOPYRAZINE DERIVATIVES AS SYK AND JAK INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-03-27 | — | — | EP | claimed |
| US-8329699-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | claimed |
| CN-120424083-B | Pyrrolo pyrimidine compound and preparation method and application thereof | 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) | 2026-02-27 | — | — | CN | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | disclosed |
| CN-116284040-B | Nitrogen-containing heterocyclic compound and medical application thereof | 华润医药研究院（深圳）有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2024-02-08 | — | — | US | disclosed |
| EP-2435432-B3 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE IRELAND UNLIMITED CO (BM) | 2023-10-25 | — | — | EP | disclosed |
| US-7410966-B2 | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| EP-1889907-A1 | NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME | Kaneka Corporation (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-7332509-B2 | Heterocyclic amides, a process for their preparation, compositions comprising them and their use | MERIAL LIMITED (US) | 2008-02-19 | — | — | US | disclosed |
| EP-1878727-A1 | 2-AMINOQUINAZOLINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-16 | — | — | EP | disclosed |
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| EP-1434485-B1 | NICOTINIC ACID-HETEROCYCLYL-AMIDES AND ANALOGOUS PYRIMIDINE DERIVATIVES FOR USE AS PESTICIDES | MERIAL LTD (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | disclosed |
| EP-1030840-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE AS DRUGS | TEIJIN LIMITED (JP) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999025686-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE AS DRUGS | TEIJIN LIMITED (JP) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261333-A1 | Use of and some novel imidazopyridines | ITK, CSNK1A1, RPS6KA1 | TP53 2698/4885TSHR 1384/4885SMN1; SMN2 1377/4885 |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | BCL2, BAX, BCL3 | TP53 57/4885TSHR 3754/4885SMN1; SMN2 2670/4885 |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | TP53 57/4885TSHR 3754/4885SMN1; SMN2 2670/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | TP53 32/4885TSHR 4653/4885SMN1; SMN2 318/4885 |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | TP53 57/4885TSHR 3754/4885SMN1; SMN2 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.